Anhui Haikang Pharmaceutical Co., Ltd. was established in 2009. It is a high-tech enterprise that produces high-end APIs such as anti-viral, anti-tumor, hypoglycemic, and anti-allergic. The company's predecessor was established in the 1990s, with more than 20 years of experience in the production of anti-virus, diabetes and anti-tumor raw materials. Subsequently, the entire enterprise moved to Anqing, Anhui. After many years of development, there are currently 35 R&D teams, quality department personnel and EHS management personnel, with a total number of more than 90, and 25 technical personnel with undergraduate degrees or above. The company has reached cooperation with East China Normal University, Anhui University, Zhejiang University of Technology, China Pharmaceutical University and Anqing University as an internship base for undergraduate and graduate students. The company has now completed the first phase of the project, obtained the pollution discharge permit, completed the occupational health prevention and control acceptance, and successfully obtained the "three-level safety production standardization" certificate and the drug production license. The company will invest in the second phase of the project from 2021 to 2022, and will build two GMP raw material drug production workshops with a total area of 10,000 square meters; 8,000 square meters of research and development buildings and warehouses. The output value of the second phase is expected to reach 200 million yuan.